{"id":"NCT02147197","sponsor":"Allergan","briefTitle":"A Study of the Efficacy and Safety of a 3-month Treatment Course of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas","officialTitle":"A Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-03-31","primaryCompletion":"2016-03-29","completion":"2016-03-29","firstPosted":"2014-05-26","resultsPosted":"2019-04-05","lastUpdate":"2019-04-30"},"enrollment":157,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Leiomyoma","Uterine Hemorrhage"],"interventions":[{"type":"DRUG","name":"Ulipristal acetate (UPA)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"UPA 5 mg","type":"EXPERIMENTAL"},{"label":"UPA 10 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study will evaluate the superiority of ulipristal acetate versus placebo for the treatment of abnormal uterine bleeding associated with uterine fibroids","primaryOutcome":{"measure":"Percentage of Participants With Absence of Bleeding During the Last 35 Consecutive Days on Treatment","timeFrame":"Last 35 consecutive days on treatment in the 12-week Treatment Period","effectByArm":[{"arm":"Placebo","deltaMin":1.8,"sd":null},{"arm":"UPA 5 mg","deltaMin":47.2,"sd":null},{"arm":"UPA 10 mg","deltaMin":58.3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":4},"locations":{"siteCount":28,"countries":["United States"]},"refs":{"pmids":["31444600","30969201","29420395"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":56},"commonTop":["Hypertension","Blood creatine phosphokinase increased","Hot flush","Nausea","Acne"]}}